Release Date: 17/09/13 15:33 Summary: Outcome of the Board Strategic Review Price Sensitive: Yes Download Document 142.01KB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling